中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (10): 770-776.doi: 10.19401/j.cnki.1007-3639.2020.10.007

• 专家述评与论著 • 上一篇    下一篇

病理学指导下的非小细胞肺癌个体化免疫治疗

李 媛   

  1. 复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2020-10-30 发布日期:2020-11-12
  • 通信作者: 李 媛 E-mail: lumoxuan2009@163.com

Personalized immunotherapy for lung cancer under the guidance of pathology

LI Yuan   

  1. Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2020-10-30 Online:2020-11-12
  • Contact: LI Yuan E-mail: lumoxuan2009@163.com

摘要: 在肺癌个体化免疫治疗时代,如何有效地筛选程序性死亡[蛋白]-1(programmed death-1,PD-1)/程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)免疫检查点抑制剂潜在获益人群成为免疫治疗时代面临的新挑战。病理科医师通过免疫组织化学检测非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中PD-L1的表达水平,可为预测PD-1/PD-L1免疫检查点抑制剂治疗晚期NSCLC的疗效和预后提供准确可靠的依据。此外,病理科医师可通过传统病理学方法观察主要病理学缓解(major pathological response,MPR)程度,进一步评价早中期肺癌免疫新辅助治疗的效果。对目前病理学诊断指导下的NSCLC个体化免疫治疗的进展以及未来的发展方向进行综述。

关键词: 非小细胞肺癌, 免疫检查点抑制剂, 免疫组织化学, 病理学评价

Abstract: In the era of personalized immunotherapy for lung cancer, how to effectively screen potential beneficiaries of programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint inhibitors has become a new challenge. The expression levels of PD-L1 in non-small cell lung cancer (NSCLC) can be detected by immunohistochemistry, which provides accurate and reliable information for predicting the efficacy of PD-1/PD-L1 immunotherapy and prognosis in advanced NSCLC. In addition, traditional pathology can be used to observe major pathological response (MPR) to further evaluate the efficacy of neoadjuvant immunotherapy for early/middle-stage NSCLC. This review summarized the current progress and future development of personalized immunotherapy for NSCLC under the guidance of pathology.

Key words: Non-small cell lung cancer, Immune checkpoint inhibitor, Immunohistochemistry, Pathology evaluation